UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

Mark David Hartley outlines a strategy he’d use to aim for a second income that gets bigger over time, by investing just £10 a day. The post £10 a day invested in UK shares could one day create a ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

GlaxoSmithKline is to sell off its famous bedtime malted milk drink Horlicks in the UK, and will also consider exiting a pharma business, its cephalosporins antibiotics franchise. This gloomy news ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

GSK has confirmed plans to sell its Horlicks business in the UK and close the site where the malted drink is made. As well as shutting the site in Slough, the pharmaceuticals giant said it will ...

Lacalle Pou “welcomed GSK's announcement of the opening of one ... bond linked to sustainability goals was discussed. The UK “encouraged exploring the cross-issuance of this bond in London ...